Formulary development at Regence BlueShield - A formula for success

Value in Health

Volumn 5, Issue 4, 2002, Pages 297-300

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG;

DECISION MAKING; DISEASE MANAGEMENT; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE PLANNING; HEALTH INSURANCE; HISTORY OF MEDICINE; MANAGED CARE; NOTE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; REGENCE BLUE SHIELD; UNITED STATES;

EID: 0005501041     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.54002.x     Document Type: Note

References (8)

1. Mather DB, Sullivan SD, Augenstein D, Fullerton DS, Atherly D. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach. Am J Manag Care 1999;5:277-85.
2. Sullivan SD, Lyles A, Luce B, Gricar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefit management organizations. Manag Care Pharm 2001;7:272-85.
3. NIHCM, May 2001. New York Times, May 8, 2001. Available at http://www nihcm.org.
4. Moretz S. Real world outcomes are the focus of new AMCP formulary format. Manag Health Care Exec 2000 May;38-43.
5. McCain J. System helps P & T committees get pharmacoeconomic data they need. Manag Care 2001;10:24C-24J.
6. Fullerton DS, Atherly D, Sullivan SD. Showing outcomes and proving value brings success. Manag Care Interface 2001;14:63-71.
7. Penna P. The Academy of Managed Care Pharmacy's format for formulary submission. Manag Care Interface 2001;14:61-2.
8. Sprague K. Regence BlueShield's mandatory data submission requirement for manufacturers: a progress report. Formulary 2000;35:514-28.